[
  {
    "ts": "2026-01-07T10:00:00+00:00",
    "headline": "DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies",
    "summary": "Collaboration with Amgen to advance a cancer target discovered using DISCO’s proprietary surfaceome mapping technology Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that was mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms of the agreement, DISCO will be eligible to receive up to $618 million total potential deal value",
    "url": "https://finance.yahoo.com/news/disco-pharmaceuticals-enters-license-agreement-100000590.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a84f70f8-74f0-37f0-b464-708e465b91e3",
      "content": {
        "id": "a84f70f8-74f0-37f0-b464-708e465b91e3",
        "contentType": "STORY",
        "title": "DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies",
        "description": "",
        "summary": "Collaboration with Amgen to advance a cancer target discovered using DISCO’s proprietary surfaceome mapping technology Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that was mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms of the agreement, DISCO will be eligible to receive up to $618 million total potential deal value",
        "pubDate": "2026-01-07T10:00:00Z",
        "displayTime": "2026-01-07T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/13afdaa94c44bab998f2dc52c7e1d189",
          "originalWidth": 1284,
          "originalHeight": 450,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1em20t4hq0JUrXMcPj1RTg--~B/aD00NTA7dz0xMjg0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/13afdaa94c44bab998f2dc52c7e1d189.cf.webp",
              "width": 1284,
              "height": 450,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GYBIhKBD4GOo9uXgFCH2yA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/13afdaa94c44bab998f2dc52c7e1d189.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/disco-pharmaceuticals-enters-license-agreement-100000590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/disco-pharmaceuticals-enters-license-agreement-100000590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "DISPF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T12:50:47+00:00",
    "headline": "Amgen buys Dark Blue Therapeutics in $840m oncology deal",
    "summary": "According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology pipeline.",
    "url": "https://www.pharmaceutical-technology.com/news/amgen-acquires-dark-blue-therapeutics-oncology-targeted-protein-degrader/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "87523deb-5568-35af-a116-36add034d1ae",
      "content": {
        "id": "87523deb-5568-35af-a116-36add034d1ae",
        "contentType": "STORY",
        "title": "Amgen buys Dark Blue Therapeutics in $840m oncology deal",
        "description": "",
        "summary": "According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology pipeline.",
        "pubDate": "2026-01-07T12:50:47Z",
        "displayTime": "2026-01-07T12:50:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/0d6ae13e5bbc77ea7b1a1553127d91fc",
          "originalWidth": 1000,
          "originalHeight": 750,
          "caption": "Amgen is acquiring UK-based biotech Dark Blue Therapeutics in a buyout worth up to $840m. Image credit: Piotr Swat via ShutterStock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3gh1PFwHf_HHyEpww1nTOA--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/0d6ae13e5bbc77ea7b1a1553127d91fc.cf.webp",
              "width": 1000,
              "height": 750,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BlBVZE5Oj73SrrXuivmrpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/0d6ae13e5bbc77ea7b1a1553127d91fc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/amgen-acquires-dark-blue-therapeutics-oncology-targeted-protein-degrader/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-buys-dark-blue-therapeutics-125047098.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]